Mallinckrodt (MNK) Stock Price, News & Analysis

Company Overview

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.14 to $0.75
• 52-Week Range: N/A
• Volume: 39,227 shs
• Average Volume: 2.62 million shs
• Market Capitalization: $1.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MNK Stock Analysis - Frequently Asked Questions

How were Mallinckrodt's earnings last quarter?

Mallinckrodt plc (NYSE:MNK) posted its quarterly earnings data on Tuesday, August, 4th. The company reported $1.89 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.55. The business's revenue was down 14.9% on a year-over-year basis.

What other stocks do shareholders of Mallinckrodt own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mallinckrodt investors own include Bristol Myers Squibb (BMY), Gilead Sciences (GILD), Micron Technology (MU), Endo International (ENDP), Bausch Health Cos (BHC), Meta Platforms (META) and Gerdau (GGB).

Company Calendar

• Last Earnings: 8/04/2020
• Today: 7/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NYSE:MNK
• CIK: 1567892
• Web: www.mallinckrodt.com
• Phone: (531) 696-0000
• Fax: N/A
• Employees: 2,700
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($116.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: -82.59%
• Pretax Margin: N/A
• Return on Equity: 20.32%
• Return on Assets: 2.49%

Debt

• Debt-to-Equity Ratio: 1.18
• Current Ratio: 0.57
• Quick Ratio: 0.31

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $47.48 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 13,170,000
• Free Float: 13,131,000
• Market Cap: $1.58 million
• Optionable: Not Optionable
• Beta: N/A